← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleJiangsu Hengrui Pharmaceutical …Phase 2

trastuzumab (Herceptin, pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

Purpura; Idiopathic Thrombocytopenic Purpura · Purpura

#Purpura#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleThe Affiliated Hospital of Qing…Phase 1

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleDan LiangPhase 2

adalimumab (Humira, reduction or discontinuation of Adalimumab)

Uveitis; Adalimumab · Uveitis

#Uveitis#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleUniversity of UtahPhase 1

regorafenib + panitumumab (regorafenib + panitumumab)

KRAS and NRAS Wild-type Colorectal Cancer · KRAS and NRAS Wild-type Colorectal Cance

#KRASandNRASWild-typeColorectalCa#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 44.4%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab+rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPreclinical

response to infliximab associated with methotrexate (response to infliximab associated with methotrexate)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGenentech, Inc.Phase 3

ranibizumab (rhuFab V2, rhuFab V2 (ranibizumab))

Macular Degeneration · Macular Degeneration

#MacularDegeneration#Antibody#Phase3#항체#면역항체+2
효능 ORR 56.4%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab (rhuMAb VEGF, rhuMAb VEGF (Bevacizumab))

Renal Cell Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 3

serplulimab、bevacizumab (serplulimab、bevacizumab)

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity Hospital, Gentofte, …Preclinical

adalimumab (Humira, subjects will receive either infliximab, adalimumab or etanercept)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

toripalimab + cetuximab + platinum (three cycles, three cycles (toripalimab + cetuximab + platinum))

Locally Advanced Hypopharyngeal Carcinoma · Locally Advanced Hypopharyngeal Carcinom

#LocallyAdvancedHypopharyngealCar#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMatthew C. BakerPhase 3

LY3090106 (tibulizumab, tibulizumab (LY3090106))

Primary Sjogren's Syndrome · Primary Sjogren's Syndrome

#PrimarySjogrensSyndrome#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleVanderbilt-Ingram Cancer CenterPreclinical

ticilimumab (ticilimumab)

Melanoma · Melanoma

#Melanoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleBeiGenePreclinical

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePreclinical

tislelizumab, etoposide, pegaspargase (tislelizumab, etoposide, pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

tocilizumab [RoActemra/Actemra] (tocilizumab [RoActemra/Actemra])

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

anti-CTLA4 (tremelimumab, tremelimumab (anti-CTLA4))

Non - Small Cell Lung Cancer NSCLC · Non - Small Cell Lung Cancer NSCLC

#Non-SmallCellLungCancerNSCLC#Antibody#Phase3#항체#면역항체+2
효능 ORR 35.5%임상시험 1상태 ACTIVE

61 / 62 페이지

← 이전다음 →